Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vivos Therapeutics

3.12
-0.0100-0.32%
Post-market: 3.02-0.1000-3.21%19:11 EDT
Volume:366.86K
Turnover:1.16M
Market Cap:23.41M
PE:-1.76
High:3.22
Open:3.10
Low:3.07
Close:3.13
52wk High:7.95
52wk Low:1.98
Shares:7.50M
Float Shares:5.43M
Volume Ratio:1.75
T/O Rate:6.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7775
EPS(LYR):-2.2184
ROE:-262.05%
ROA:-42.48%
PB:5.11
PE(LYR):-1.41

Loading ...

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

GlobeNewswire
·
Sep 30

Vivos Therapeutics Inc. Announces Date for 2025 Annual Stockholders Meeting

Reuters
·
Sep 29

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

GlobeNewswire
·
Sep 17

Vivos Therapeutics Inc. Files Prospectus Supplement for Continued Sale of Up to $5.83 Million in Common Stock Through ATM Offering

Reuters
·
Sep 13

Strategic Growth and Market Expansion: Vivos Therapeutics’ Buy Rating and Raised Price Target

TIPRANKS
·
Sep 11

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 09

Vivos Therapeutics Q2 EPS $(0.55) Misses $(0.35) Estimate, Sales $3.820M Beat $3.783M Estimate

Benzinga
·
Aug 20

BRIEF-Vivos Therapeutics Q2 Net Income USD -5.013 Million

Reuters
·
Aug 20

Vivos Therapeutics Inc - Q2 REV $3.8 Mln

THOMSON REUTERS
·
Aug 20

Vivos Therapeutics Q2 Basic EPS USD -0.55

THOMSON REUTERS
·
Aug 20

Vivos Therapeutics Q2 Gross Profit USD 2.11 Million

THOMSON REUTERS
·
Aug 20

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

THOMSON REUTERS
·
Aug 20

Press Release: Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call

Dow Jones
·
Aug 19

Vivos Therapeutics : Anticipates Material Increase in Net Loss for Three Months Ended June 30, 2025 as Compared to Three Months Ended June 30, 2024

THOMSON REUTERS
·
Aug 15

Vivos Therapeutics Inc. Delays Q2 2025 Financial Report Due to Recent Acquisition

Reuters
·
Aug 15

Vivos Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Aug 08

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

GlobeNewswire
·
Jul 30

Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep

Dow Jones
·
Jul 02

BRIEF-Vivos Therapeutics Inc - Vidasleep Oral Appliance Approved By CMS Pdac

Reuters
·
Jul 01

Vivos Therapeutics Inc. Files Initial Beneficial Ownership Statement for Michael C. Skaff

Reuters
·
Jun 21